Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics' Q4 Spending Swells in Preparation for 2008 Dx Launches

NEW YORK (GenomeWeb News) – Rosetta Genomics today said in its earnings report for the fourth quarter of 2007 that it is “solidly on target” to launch three diagnostic microRNA tests in the coming year, but as it currently has no products on the market it posted no revenues for 2007.
 
In addition, the company’s net loss nearly tripled as it spent more on increased R&D and selling and general expenses rose.  
 
Rosetta is focused on developing diagnostics for squamous and non-squamous non-small cell lung cancer, mesothelioma and adenocarcinoma, and cancer of unknown primary, as well as a therapeutic for liver cancer.
 
Rosetta Genomics posted a net loss of $8.2 million, or $.69 per share, compared with a loss of $2.1 million, or $.82 per share, in the comparable quarter last year.
 
Research and development spending swelled 58 percent year over year to $2.1 million from $1.3 million, while SG&A costs rose 58 percent to $1.4 million from $895,000 year over year.
 
For full-year 2007, research and development spending increased 33 percent in 2007 to $6.4 million from $4.8 million, while SG&A costs rose 38 percent to $4.6 million in fiscal 2007 compared with $3.4 million the previous year.
 
Net loss for 2007 ballooned 93 percent to $14.7 million, or $1.32 per share, from $7.6 million, or $2.98 per share, in 2006. 

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.